From Tysabri to bapi and back to the drawing board: Dale Schenk speaks

Dale Schenk is the scientist behind both the hugely successful multiple sclerosis treatment Tysabri (natalizumab) and the much-hyped investigational Alzheimer's disease vaccination bapineuzumab, which crashed spectacularly in Phase III trials last year. Now heading up the newly independent Prothena, which was demerged from Elan late last year, he speaks to Scrip's Eleanor Malone as he embarks on his third adventure as a biotech entrepreneur.

Dale Schenk is the scientist behind both the hugely successful multiple sclerosis treatment Tysabri (natalizumab) and the much-hyped investigational Alzheimer's disease vaccination bapineuzumab, which crashed spectacularly in Phase III trials last year. Now heading up the newly independent Prothena, which was demerged from Elan late last year, he speaks to Scrip's Eleanor Malone as he embarks on his third adventure as a biotech entrepreneur.

Before becoming chief scientific officer at Elan, Dr Schenk's career began in the 1980s with Californian Biotechnology (later renamed Scios...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Therapeutic Category

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.